ITTM S.A. is part of the IMI2 TransBioLine project funded by the European Union's Horizon 2020 programme

Friday, 14 June 2019

Innovative Medicines Initatiative (IMI) launches Translational Safety Biomarker Pipeline (TransBioLine) Project to enable developement and implementation of novel safety biomarkers

The Innovative Medicines Initiative  announced the launch of the Translational Safety Biomarker Pipeline Project, a five-year program to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular, and central nervous system) for application in drug development.

The TransBioLine Project is a consortium of 27 partners across pharmaceutical companies, small and medium-sized enterprises, and academic institutions from 10 European countries, and is coordinated by the University of Zurich with Pfizer Inc. as the industry lead. It is funded by the IMI Joint Undertaking as a public-private partnership, with a budget of 28M€ and will be active through 2024.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies.

ITTM © 2019 - maintained by CTMS